Author: Ravi Shankar

SYDNEY, AUSTRALIA, Nov. 11, 2026 (GLOBE NEWSWIRE) — Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a biotechnology company developing novel immunotherapies, today announced the grant of a new patent (number 12,788,796) entitled “Combined Preparations for the Treatment of Cancer or Infection” by the United States Patent and Trademark Office (USPTO).

With this latest grant, Immutep now holds five United States patents within this patent family. The portfolio has expanded progressively through a series of patents granted in December 2020, March 2021, June 2023, July 2026 and, most recently, this latest patent.

The claims of the new patent build on the protection provided by the four previously granted patents and are directed to combined preparations and pharmaceutical compositions comprising eftilagimod alfa (“efti”) and a PD-1 pathway inhibitor. Specifically, the claims encompass combinations with BMS-936559, durvalumab, atezolizumab and avelumab. The expiry date of the patent is 23 March 2038 (including 806 days of patent term adjustment).

The patent grant provides additional protection for the use of efti in combination with PD-1 pathway inhibitors, a key class of immunotherapies used in modern cancer treatment, further expanding Immutep’s patent portfolio covering efti-based combination therapies. Immutep has also filed a continuation application to pursue additional embodiments of the invention.

Marc Voigt, CEO of Immutep, said: “We are pleased to receive this latest US patent grant, which further strengthens the intellectual property protection surrounding efti. As we pursue our focused development strategy for efti, a good patent portfolio remains an important strategic asset, supporting future development and partnering opportunities. We believe in the potential of this unique biomolecule and that carefully selected clinical settings could provide meaningful opportunities for continued evaluation and value creation.”

About Eftilagimod Alfa (Efti)
Eftilagimod alfa (efti) is Immutep’s proprietary soluble LAG-3 protein and MHC Class II agonist that activates antigen-presenting cells through the MHC Class II pathway, engaging both innate and adaptive immunity, including the priming of cytotoxic CD8+ T cells and the production of co-stimulatory signals and cytokines. Its favourable safety profile enables combination with anti-PD-(L)1 therapy, radiotherapy and/or chemotherapy. Efti has received Fast Track designation from the U.S. Food and Drug Administration in first-line head and neck squamous cell carcinoma and first-line non-small cell lung cancer, and Orphan Drug Designation in soft tissue sarcoma.

About Immutep
Immutep is a clinical-stage biotechnology company developing novel immunotherapies for cancer and autoimmune diseases. The Company is a pioneer in the understanding and advancement of therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), and its diversified product portfolio harnesses LAG-3’s ability to stimulate or suppress the immune response. Immutep is dedicated to leveraging its expertise to bring innovative treatment options to patients in need and to maximise value for shareholders. For more information, please visit www.immutep.com.

Forward-Looking Statements
This press release contains forward-looking statements, including statements regarding anticipated clinical development, regulatory progress and potential benefits of eftilagimod alfa. These forward-looking statements are based on current expectations, estimates and projections, and involve known and unknown risks, uncertainties and other important factors that could cause actual results to differ materially from those expressed or implied in such statements.

Factors that could cause actual results to differ materially include risks associated with clinical trial outcomes, regulatory developments, and the Company’s ability to advance its product candidates.
Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date of this release. Immutep undertakes no obligation to update or revise such statements, except as required by applicable law.

Disclaimer
This announcement has been prepared for informational purposes only and does not constitute an offer to sell, or a solicitation of an offer to buy, securities in any jurisdiction.

Australian Investors/Media:
Eleanor Pearson, Sodali & Co.
+61 2 9066 4071; eleanor.pearson@sodali.com

U.S. Investors/Media:
Matthew Beck, astr partners
+1 (917) 415 1750; matthew.beck@astrpartners.com

SAN JUAN CAPISTRANO, Calif., Nov. 10, 2026 (GLOBE NEWSWIRE) — The Ensign Group, Inc. (Nasdaq: ENSG), which invests in facilities that provide skilled nursing and senior living services, physical, occupational and speech therapies, and other rehabilitative and healthcare services, today announced that 101 of its independently operating affiliates have been recognized and included in the listing of the 2027 Best Nursing Homes by U.S. News & World Report.

Since 2009, U.S. News’ annual Best Nursing Homes analysis has served as an independent, data-driven guide for families navigating short-term rehabilitation or comprehensive long-term care choices. Each Ensign-affiliated facility on the list earned a High Performing rating – the highest distinction awarded by U.S. News – reflecting outstanding quality in Short-Term Rehabilitation, Long-Term Care, or both.

Recognizing only 18% of evaluated facilities across the nation for 2027, U.S. News’ Best Nursing Homes designation reflects a high standard of care. This designation is reserved only for skilled nursing facilities that satisfy U.S. News’ rigorous, proprietary assessment criteria demonstrating a consistent and superior commitment to quality and resident-centered care.

“I am deeply grateful to the caregivers and leaders who earned this important recognition,” said Barry Port, Ensign’s Chief Executive Officer. “Being named among the nation’s best nursing homes is evidence of their dedication to clinical excellence and reflects the exceptional care they deliver to residents every day.”

“Earning a High Performing rating from U.S. News reflects a continuous, facility-wide commitment to superior resident care,” said Jordan Derk, Ph.D., senior care researcher at U.S. News. “When families see this distinction, they can feel confident that this skilled nursing facility has demonstrated exceptional outcomes.”

For the 2027 edition, U.S. News evaluated more than 14,600 nursing homes in the United States, assessing key indicators such as hospital readmission rates, staffing levels, health inspection results and other indicators of quality. The 2027 U.S. News Best Nursing Homes ratings rely on a comprehensive evaluation framework, assessing 17 distinct quality measures across both Short-Term Rehabilitation and Long-Term Care categories to deliver a thorough analysis of overall nursing home quality.

For patients and families evaluating their options, choosing a skilled nursing facility recognized by U.S. News with a Best Nursing Home designation provides a trusted starting point to discuss in consultation with their healthcare provider.

For more information, visit USNews.com and use #BestNursingHomes on Facebook, Instagram, LinkedIn, Threads, TikTok and X.

About U.S. News & World Report
U.S. News & World Report is the global leader for journalism that empowers consumers, citizens, business leaders and policy officials to make confident decisions in all aspects of their lives and communities. A multifaceted media company, U.S. News provides unbiased rankings, independent reporting and analysis, and consumer advice to millions of people on USNews.com each month. A pillar in Washington for more than 90 years, U.S. News is the trusted home for in-depth and exclusive insights on education, health, politics, the economy, insurance, personal finance, travel, automobiles, real estate, careers and consumer products and services.

About Ensign:
The Ensign Group, Inc.’s independent operating subsidiaries provide a broad spectrum of skilled nursing and senior living services, physical, occupational and speech therapies and other rehabilitative and healthcare services at 418 healthcare facilities in Alabama, Alaska, Arizona, California, Colorado, Florida, Idaho, Iowa, Kansas, Nebraska, Nevada, Oregon, South Carolina, Tennessee, Texas, Utah, Washington and Wisconsin. More information about Ensign is available at http://www.ensigngroup.net.

Contact Information:
media@ensignservices.net (949) 487-9500

CALGARY, Alberta, Nov. 10, 2026 (GLOBE NEWSWIRE) — Calfrac Well Services Ltd. (“Calfrac” or “the Company”) (TSX: CFW) announces its financial and operating results for the three and nine months ended September 30, 2026. The following press release should be read in conjunction with the management’s discussion and analysis and interim consolidated financial statements and notes thereto as at September 30, 2026. All financial amounts and measures are expressed in Canadian dollars unless otherwise indicated.

THIRD QUARTER 2026 HIGHLIGHTS

In the period, the Company:

• generated revenue of $365.7 million, an increase of 13 percent compared to $323.4 million in the third quarter of 2025, driven by stronger activity and improved utilization in North America partially offset by reduced activity in Argentina;
• generated Adjusted EBITDA of $54.5 million (15 percent of revenue) versus $48.5 million (15 percent of revenue) in the third quarter of 2025 as improved profitability in North America was offset by reduced profitability in Argentina;
• reported net income of $16.3 million ($0.16 per share diluted) compared with $4.3 million ($0.05 per share diluted) during the third quarter in 2025, reflecting stronger operating performance and lower interest expense;
• incurred capital expenditures of $22.0 million, including investment in the expansion of the Company’s coiled tubing and cementing service lines in Argentina, while maintaining a disciplined approach to capital allocation and high asset utilization;
• generated free cash flow of $11.1 million and cash flow from operating activities of $31.8 million, supporting debt reduction and continued strengthening of the Company’s balance sheet;
• repatriated US$4.2 million of cash from Argentina during the quarter, reflecting the continued easing of Argentina’s foreign exchange restrictions and improving access to cash repatriation mechanisms, thereby enhancing the Company’s financial flexibility; and
• reduced net debt by $10.7 million during the third quarter and $81.7 million, or 42 percent, since December 31, 2025, to $115.1 million, reflecting sustained free cash flow generation and continued progress toward the Company’s capital structure objectives.

SELECT FINANCIAL HIGHLIGHTS
Three Months Ended September 30,	2026	2025		Change
(C$000s, except per share amounts)	($)	($)		(%)
(unaudited)
Revenue	365,713	323,408		13
Adjusted EBITDA(1)	54,515	48,468		12
Adjusted EBITDA %(1)	14.9	15.0		(1	)
Cash flows provided by (used in) operating activities	31,812	30,099		6
Capital expenditures	21,973	32,815		(33	)
Free cash flow(1)	11,142	(1,207	)	NM
Net income	16,289	4,295		279
Per share – basic(2)	0.16	0.05		220
Per share – diluted(2)	0.16	0.05		220
As at	September 30, 2026	December 31, 2025		Change
(C$000s) (unaudited)	($)	($)		(%)
Cash and cash equivalents	17,008	6,664		155
Working capital, calculated as:
Excluding cash and cash equivalents and the current portion of long-term debt	218,631	189,304		15
Including cash and cash equivalents and the current portion of long-term debt	182,306	155,968		17
Total assets, end of period	1,104,391	1,047,199		5
Long-term debt, end of period(3)	132,081	203,425		(35	)
Net debt(1)(4)	115,073	196,761		(42	)
Total equity, end of period	755,872	664,279		14

⁽¹⁾ Refer to “Non-GAAP Measures” on page 3 for further information.
⁽²⁾ Basic and diluted shares outstanding have been restated to show the comparative impact of the rights offering that was completed in December 2025.
⁽³⁾ Refer to note 3 of the consolidated interim financial statements for further information.
⁽⁴⁾ Refer to note 9 of the consolidated interim financial statements for further information.

CEO’S MESSAGE
Throughout 2026, Calfrac has continued to generate meaningful free cash flow while materially strengthening its balance sheet and enhancing financial flexibility. These results reflect the disciplined execution of our teams, an ongoing focus on operational efficiency, and our commitment to directing personnel, equipment, and capital to the highest-returning opportunities across our business.

During the third quarter, our North American operations delivered significantly improved financial performance, supported by a more favourable activity mix, stronger asset utilization, and the continued benefits of the strategic repositioning of our U.S. fracturing fleet. In Argentina, a more pronounced seasonal slowdown and late-quarter customer scheduling changes affected fracturing and wireline activity. However, strong year-over-year growth in our coiled tubing and cementing operations demonstrated the benefits of expanding and diversifying our service offerings in the Vaca Muerta.

Our financial position continued to strengthen during the quarter. Net debt decreased to approximately $115 million at September 30, 2026, representing a reduction of more than 40 percent since the beginning of the year and resulting in the Company’s lowest leverage position in more than a decade. Importantly, this progress was achieved while continuing to fund strategic growth initiatives, demonstrating the strength of our free cash flow generation and disciplined approach to capital allocation.

Calfrac is entering the next stage of its development with a significantly stronger balance sheet, an increasingly efficient operating platform and attractive growth opportunities across its geographic regions and service lines. We remain focused on accelerating the momentum generated throughout 2026 and creating long-term value for our employees, customers, and shareholders.

OUTLOOK

NORTH AMERICA
Demand for completion services is expected to remain constructive through the balance of 2026 and into the first quarter of 2027, supported by elevated crude oil prices and customer activity levels across the Company’s key operating regions. The strategic repositioning of the Company’s equipment from Pennsylvania to the Rockies and Bakken regions has improved asset utilization and financial returns by directing equipment toward more attractive operating opportunities. The Company also realized modest pricing improvements in its core U.S. operating districts during 2026. The benefits of the Company’s fleet repositioning, combined with improving industry fundamentals, are expected to support stronger asset utilization and returns as market conditions continue to improve.

The Company remains focused on selectively deploying its fracturing fleets to opportunities that provide the best combination of pricing, utilization, and longevity across its North American footprint. Seasonal factors, including winter operating conditions and the year-end holiday period, are expected to periodically impact utilization during the fourth quarter of 2026 and first quarter of 2027. However, the current commodity price environment is expected to support more consistent customer activity relative to the comparable period in the prior year.

Industry pressure pumping fundamentals continue to improve as available capacity remains disciplined, and customer demand remains constructive. As a result, pricing conditions are expected to improve gradually over the coming quarters, with the U.S. market anticipated to continue leading the recovery. The Company is also continuing to gain experience applying its completion capabilities in the geothermal market and is evaluating opportunities to expand its participation in this emerging end market.

ARGENTINA
Momentum in the Vaca Muerta resource play continues to build as multiple export and transportation infrastructure projects are anticipated to enter service over the medium term, supporting increased hydrocarbon exports and providing a pathway for accelerated production growth. These developments, combined with continued multi-billion-dollar investment commitments from major international and domestic operators, reinforce the Company’s view that Vaca Muerta represents one of the most attractive unconventional resource opportunities globally.

Fracturing activity has recently recovered from the seasonal slowdown experienced during the third quarter and start of the fourth quarter, which was more pronounced than anticipated due to late-quarter customer scheduling changes. The Company expects improved utilization for the balance of the year and the start of the first quarter of 2027. The impact of the seasonal slowdown was concentrated primarily in the Company’s fracturing and associated wireline operations, while coiled tubing and cementing activity increased compared with the prior-year quarter. These results demonstrate the benefits of the continued expansion and diversification of the Company’s service offerings in the Vaca Muerta.

Demand for coiled tubing and cementing services remains robust, and the Company expects this momentum to continue as the previously announced service-line expansions commence operations in 2027. The Company remains focused on deploying capital and operational resources toward opportunities that strengthen its integrated completion capabilities, enhance asset utilization and support customer activity in the region.

CORPORATE
The Company remains focused on generating free cash flow, maintaining capital discipline, and further strengthening its balance sheet. The significant reduction in leverage achieved during 2026 has enhanced financial flexibility and positioned the Company to pursue selective, high-return growth opportunities across its operating regions and service lines. As market conditions continue to improve, management intends to allocate capital prudently toward opportunities that improve asset utilization, support long-term growth, and enhance shareholder value.

NON-GAAP MEASURES
Certain supplementary measures presented in this press release, including Adjusted EBITDA, Adjusted EBITDA percentage, Free Cash Flow, and Net Debt do not have any standardized meaning under International Financial Reporting Standards (IFRS) and, because IFRS have been incorporated as Canadian generally accepted accounting principles (GAAP), these supplementary measures are also non-GAAP measures. These measures have been described and presented to provide shareholders and potential investors with additional information regarding the Company’s financial results, liquidity, and ability to generate funds to finance its operations. These measures may not be comparable to similar measures presented by other entities and are explained below.

Adjusted EBITDA is defined as net income or loss for the period less interest, taxes, depreciation and amortization, foreign exchange losses (gains), non-cash stock-based compensation, and gains and losses that are extraordinary or non-recurring. Adjusted EBITDA is presented because it gives an indication of the results from the Company’s principal business activities prior to consideration of how its activities are financed and the impact of foreign exchange, taxation and depreciation and amortization charges. Adjusted EBITDA is used by management to evaluate the performance of the Company and is also used as a basis for monitoring the Company’s compliance with covenants under the credit facility. Adjusted EBITDA for the period was calculated as follows:

Three Months Ended September 30,	2026	2025
(C$000s) (unaudited)	($)	($)
Net income	16,289	4,295
Add back (deduct):
Depreciation	31,613	29,712
Foreign exchange losses (gains)	1,624	8,583
Loss (gain) on disposal of property, plant and equipment	269	125
Restructuring charges	1,431	1,842
Stock-based compensation	393	—
Interest, net	2,453	6,800
Income taxes	443	(2,889	)
Adjusted EBITDA	54,515	48,468

Adjusted EBITDA percentage is a non-GAAP financial ratio that is determined by dividing Adjusted EBITDA by revenue for the corresponding period.

Free cash flow is defined as net cash flows provided by or used in operating activities less lease obligation principal repayments and capital expenditures adjusted for proceeds received from the disposition of property, plant, and equipment. Free cash flow is used by management to assess the Company’s ability to generate cash from operations after funding maintenance and growth capital requirements and meeting key financial obligations. Management believes this measure provides investors with useful information regarding the Company’s capacity to reduce debt, maintain financial flexibility, and allocate capital in accordance with its strategic priorities. Free cash flow does not have a standardized meaning under IFRS Accounting Standard and may not be comparable to similar measures presented by other issuers.

Three Months Ended September 30,	2026		2025
(C$000s)	($)		($)
Net cash flows provided by (used in) operating activities	31,812		30,099
Add back (deduct):
Lease obligation principal repayments	(2,572	)	(2,057	)
Net capital expenditures	(18,098	)	(29,249	)
Free cash flow	11,142		(1,207	)

Net Debt is defined as long-term debt less unamortized debt issuance costs less cash and cash equivalents. The calculation of net debt is disclosed in note 9 to the Company’s consolidated interim financial statements for the corresponding period.

OTHER NON-STANDARD FINANCIAL TERMS

MAINTENANCE CAPITAL
Maintenance capital refers to expenditures in respect of capital additions, replacements, and major refurbishments required to sustain the operating capacity, functionality, and useful life of the Company’s existing assets, equipment, and technology within their current specifications and capabilities.

OPTIMIZATION CAPITAL
Optimization capital refers to capital investments made to enhance the operating capabilities of the Company’s existing service fleet, including equipment upgrades, technology enhancements, emissions-reductions initiatives, automation, and other modifications that improve performance, reliability, efficiency, safety, or customer service capabilities. Such expenditures are distinct from maintenance capital required to sustain current operations and expansion capital intended to increase fleet capacity.

EXPANSION CAPITAL
Expansion capital refers to expenditures for new assets, equipment and technology that expand the size, capacity or scale of the Company’s operating fleets and operations, including investments in incremental pumping horsepower, coiled tubing units, wireline units, and ancillary operating equipment.

WORKING CAPITAL
Working capital is calculated as total current assets less total current liabilities. The Company has also provided a separate calculation of working capital that excludes cash and cash equivalents as well as the current portion of long-term debt as management believes this is a useful liquidity measure for investors and other stakeholders.

BUSINESS RISKS
The business of Calfrac is subject to certain risks and uncertainties. Prior to making any investment decision regarding Calfrac, investors should carefully consider, among other things, the risk factors set forth in the Company’s most recently filed Annual Information Form under the heading “Risk Factors” which is available on the SEDAR+ website at www.sedarplus.ca under the Company’s profile. Copies of the Annual Information Form may also be obtained on request without charge from Calfrac at Suite 601, 407 – 8th Avenue S.W., Calgary, Alberta, Canada, T2P 1E5, or at www.calfrac.com.

ADDITIONAL INFORMATION
Calfrac’s common shares are publicly traded on the Toronto Stock Exchange under the trading symbol “CFW”.

Calfrac provides specialized oilfield services to exploration and production companies designed to increase the production of hydrocarbons from wells with operations focused throughout North America and Argentina.

Further information regarding Calfrac Well Services Ltd., including the most recently filed Annual Information Form, can be accessed on the Company’s website at www.calfrac.com or under the Company’s profile at www.sedarplus.ca.

CONSOLIDATED STATEMENTS OF OPERATIONS
	Three Months Ended Sep. 30,				Nine Months Ended Sep. 30,
	2026		2025		2026		2025
(C$000s, except per share data)	($)		($)		($)		($)
Revenue	365,713		323,408		1,097,765		1,095,756
Cost of sales	330,085		289,810		972,130		967,566
Gross profit	35,628		33,598		125,635		128,190
Expenses
Selling, general and administrative	14,550		16,684		46,393		48,326
Foreign exchange losses (gains)	1,624		8,583		(391	)	16,819
Loss (gain) on disposal of property, plant and equipment	269		125		(4,277	)	1,150
Interest, net	2,453		6,800		8,929		22,705
	18,896		32,192		50,654		89,000
Income before income tax	16,732		1,406		74,981		39,190
Income tax expense (recovery)
Current	(933	)	(1,969	)	13,148		25,248
Deferred	1,376		(920	)	(5,165	)	(13,474	)
	443		(2,889	)	7,983		11,774
Net income from continuing operations	16,289		4,295		66,998		27,416
Net income (loss) from discontinued operations	—		622		—		(2,081	)
Net income	16,289		4,917		66,998		25,335
Earnings (loss) per share – basic			Restated				Restated
Continuing operations	0.16		0.05		0.67		0.31
Discontinued operations	—		0.01		—		(0.02	)
	0.16		0.06		0.67		0.29
Earnings (loss) per share – diluted
Continuing operations	0.16		0.05		0.67		0.31
Discontinued operations	—		0.01		—		(0.02	)
	0.16		0.06		0.67		0.29

CONSOLIDATED BALANCE SHEETS
	September 30,		December 31,
	2026		2025
(C$000s)	($)		($)
ASSETS
Current assets
Cash and cash equivalents	17,008		6,664
Accounts receivable	322,042		242,348
Inventories	84,189		98,291
Prepaid expenses and deposits	12,562		10,084
	435,801		357,387
Non-current assets
Property, plant and equipment	631,293		656,096
Right-of-use assets	14,148		16,247
Deferred income tax assets	23,149		17,469
	668,590		689,812
Total assets	1,104,391		1,047,199
LIABILITIES AND EQUITY
Current liabilities
Accounts payable and accrued liabilities	185,483		134,110
Income taxes payable	6,217		18,778
Current portion of long-term debt	53,333		40,000
Current portion of lease obligations	8,462		8,531
	253,495		201,419
Non-current liabilities
Long-term liabilities	1,102		—
Long-term debt	78,748		163,425
Lease obligations	6,646		9,982
Deferred income tax liabilities	8,528		8,094
	95,024		181,501
Total liabilities	348,519		382,920
Capital stock	958,266		946,654
Contributed surplus	72,642		76,225
Accumulated deficit	(282,224	)	(349,222	)
Accumulated other comprehensive income (loss)	7,188		(9,378	)
Total equity	755,872		664,279
Total liabilities and equity	1,104,391		1,047,199

CONSOLIDATED STATEMENTS OF CASH FLOWS
	Three Months Ended Sep. 30,				Nine Months Ended Sep. 30,
	2026		2025		2026		2025
(C$000s)	($)		($)		($)		($)
CASH FLOWS PROVIDED BY (USED IN)
OPERATING ACTIVITIES
Net income from continuing operations	16,289		4,295		66,998		27,416
Adjusted for the following:
Depreciation	31,613		29,712		92,965		94,085
Stock-based compensation	393		—		809		(925	)
Net gain on foreign currency forwards not qualifying as hedges	—		233		—		40
Unrealized foreign exchange losses (gains)	754		5,618		(4,650	)	16,027
Loss (gain) on disposal of property, plant and equipment	269		125		(4,277	)	1,150
Interest, net	2,453		6,800		8,929		22,705
Interest paid	(2,273	)	(10,846	)	(8,813	)	(26,935	)
Deferred income taxes	1,376		(920	)	(5,165	)	(13,474	)
Changes in non-cash working capital	(19,062	)	(4,918	)	(23,091	)	(23,492	)
Cash flows provided by operating activities from continuing operations	31,812		30,099		123,705		96,597
Cash flows provided by operating activities from discontinued operations	—		16,121		—		27,554
Net cash flows provided by operating activities	31,812		46,220		123,705		124,151
INVESTING ACTIVITIES
Purchase of property, plant and equipment	(20,623	)	(31,786	)	(49,451	)	(113,555	)
Proceeds on disposal of property, plant and equipment	1,733		2,141		6,081		5,106
Proceeds on disposal of right-of-use assets	792		396		1,726		1,091
Cash flows used in investing activities from continuing operations	(18,098	)	(29,249	)	(41,644	)	(107,358	)
Cash flows used in investing activities from discontinued operations	—		(1,194	)	—		(7,495	)
Net cash flows used in investing activities	(18,098	)	(30,443	)	(41,644	)	(114,853	)
FINANCING ACTIVITIES
Issuance of long-term debt, net of debt issuance costs	10,000		18,622		40,811		68,622
Long-term debt repayments	(13,334	)	(65,000	)	(112,667	)	(75,000	)
Lease obligation principal repayments	(2,572	)	(2,057	)	(6,979	)	(7,854	)
Net proceeds on issuance of common shares	44		—		7,220		71
Cash flows used in financing activities from continuing operations	(5,862	)	(48,435	)	(71,615	)	(14,161	)
Cash flows used in financing activities from discontinued operations	—		—		—		—
Net cash flows used in financing activities	(5,862	)	(48,435	)	(71,615	)	(14,161	)
Effect of exchange rate changes on cash and cash equivalents	(317	)	(3,978	)	(102	)	(16,859	)
Increase (decrease) in cash and cash equivalents	7,535		(36,636	)	10,344		(21,722	)
Cash and cash equivalents, beginning of period	9,473		65,690		6,664		50,776
Cash and cash equivalents, end of period	17,008		29,054		17,008		29,054

ADVISORIES
FORWARD-LOOKING STATEMENTS
In order to provide Calfrac shareholders and potential investors with information regarding the Company and its subsidiaries, including management’s assessment of Calfrac’s plans and future operations, certain statements contained in this press release, including statements that contain words such as “seek”, “anticipate”, “plan”, “continue”, “estimate”, “expect”, “may”, “will”, “project”, “predict”, “potential”, “targeting”, “intend”, “could”, “might”, “should”, “believe”, “forecast” or similar words suggesting future outcomes, are forward-looking statements or forward-looking information within the meaning of applicable securities laws (collectively, “forward-looking statements”).

In particular, forward-looking statements in this press release include, but are not limited to, statements with respect to the expectations regarding trends in, and growth prospects of, the global oil and gas industry; the supply and demand fundamentals of the pressure pumping industry; activity, demand, utilization and outlook for the Company’s North America and Argentina operating segments, including (a) the constructive outlook in North America through the balance of 2026 and into the first quarter of 2027, supported by elevated crude oil prices, the expected benefits of the Company’s fleet repositioning to the Rockies and Bakken regions, and the anticipated gradual improvement in pricing conditions led by the U.S. market, (b) the expected impact of seasonal factors on North American utilization during the fourth quarter of 2026 and first quarter of 2027, and (c) the expectation that fracturing activity in the Vaca Muerta shale play in Argentina will remain elevated through the balance of 2026 and into the first quarter of 2027, and the robust medium-term outlook for the play due to anticipated export and transportation infrastructure projects and continued investment from operators in the basin; operating and financing strategies, performance, priorities, metrics and estimates, including the Company’s plans to continue to (a) leverage the Company’s diversified geographies and service lines to direct assets, personnel and capital to the highest and best use, and (b) strengthen the balance sheet while pursuing select high-return investment opportunities; capital investment plans, including the expected timing and benefits of the coiled tubing and cementing service-line expansions in Argentina, which are expected to commence operations in 2027; the Company’s debt, liquidity and financial position, including the Company’s flexibility to reinvest in its core business while maintaining a disciplined approach to capital allocation; input costs, margin and service pricing trends and strategies; the Company’s ability and intentions to repatriate cash from Argentina; future financial resources and performance; future costs or potential liabilities; the Company’s service quality, safety record and competitive position; accounting policies, practices, standards and judgments of the Company; and the Company’s expectations and intentions with respect to the foregoing.

These statements are derived from certain assumptions and analyses made by the Company based on its experience and perception of historical trends, current conditions, expected future developments and other factors that it believes are appropriate in the circumstances, including, but not limited to, the economic and political environment in which the Company operates, including the continued implementation of Argentina’s economic reforms and investments in its oil and gas industry and the timely completion of export and transportation infrastructure in the Vaca Muerta, as well as the current state of the trade relations between Canada and the U.S. and its expected impact on the pressure pumping market in North America; the Company’s expectations for its customers’ capital budgets, demand for services and geographical areas of focus; prevailing and anticipated crude oil and natural gas prices; the anticipated effects of artificial intelligence power requirements, and the commissioning of liquefied natural gas export terminals on supply and demand fundamentals for oil and natural gas; industry equipment levels, including the number and type of active fracturing fleets marketed by the Company’s competitors; the continued effectiveness of cost reduction and efficiency measures instituted by the Company; the Company’s existing contracts and the status of current negotiations with key customers and suppliers; the likelihood that the current tax and regulatory regime will remain substantially unchanged; the level of merger and acquisition activity among oil and gas producers and its impact on the demand for well completion services; the effect of environmental, social and governance factors on customer and investor preferences and capital deployment; and the current status of the military conflicts in Ukraine and the Middle East (including its impact on shipping in the Strait of Hormuz and Bab al-Mandab Strait), U.S. and Venezuelan energy policies, and OPEC+ production decisions—and their effect on global oil and natural gas demand.

Forward-looking statements are subject to a number of known and unknown risks and uncertainties that could cause actual results to differ materially from the Company’s expectations. Such risk factors include but are not limited to: (A) industry risks, including but not limited to, global economic conditions and the level of exploration, development and production for oil and natural gas in North America and Argentina; an intensely competitive oilfield services industry; a shift in strategy by exploration and production companies prioritizing shareholder returns over production growth; excess equipment levels; and hazards inherent in the industry; (B) geopolitical risks, including but not limited to, international conflict; changes to the global trading system; shifts in government policy; foreign operations exposure, including risks relating to repatriation of cash from foreign jurisdictions, unsettled political conditions, war, foreign exchange rates and controls and sanctions; (C) business operations risks, including but not limited to, fleet reinvestment risk; a concentrated customer base; cybersecurity risks; risks related to artificial intelligence and technology; constraints on demand for the Company’s services due to mergers and acquisition activities; seasonal volatility; failure to maintain Company’s safety standards and record; and impacts of extreme weather and drought; (D) financial risks, including but not limited to, restrictions on the Company’s access to capital; direct and indirect exposure to volatile credit markets, including interest rate risk; fluctuations in currency exchange rates; and price escalation and availability of raw materials, diesel fuel and component parts; and (E) legal and regulatory risks, including but not limited to, health, safety and environmental laws and regulations; legal and administrative proceedings; federal, provincial and state legislative and regulatory initiatives and laws; and the direct and indirect costs of various existing and proposed climate change regulations. Further information about these and other risks and uncertainties may be found under the heading “Business Risks” above.

Consequently, all of the forward-looking statements made in this press release are qualified by these cautionary statements and there can be no assurance that actual results or developments anticipated by the Company will be realized, or that they will have the expected consequences or effects on the Company or its business or operations. These statements speak only as of the respective date of this press release or the document incorporated by reference herein. The Company assumes no obligation to update publicly any such forward-looking statements, whether as a result of new information, future events or otherwise, except as required pursuant to applicable securities laws.

For further information, please contact:
Tyler Dahlseide, Chief Executive Officer
Scarlett Crockatt, Chief Financial Officer

Telephone: 403-266-6000
www.calfrac.com

IRVINE, Calif., Nov. 10, 2026 (GLOBE NEWSWIRE) — Phoenix Energy One, LLC (NYSE American, PHXE.P) (“Phoenix Energy” or the “Company”), an energy company focused on oil and gas exploration and production across key U.S. basins, today reported its financial and operating results for the third quarter ended September 30, 2026, and raised its full-year 2026 outlook, on Form 10-Q with the U.S. Securities and Exchange Commission.

Q3 2026 Highlights

• Generated total revenues of $460.4 million, net loss of $1.4 million, EBITDA of $148.6 million, and Adjusted EBITDA of $207.8 million in Q3 2026, as compared to total revenues of $189.0 million, net income of $8.5 million, EBITDA of $92.6 million, and Adjusted EBITDA of $88.9 million in Q3 2025;
• Cash flow provided by operating activities was $489.0 million for the nine months ended September 30, 2026, as compared to $204.7 million for the nine months ended September 30, 2025;
• Achieved the Company’s highest quarterly gross crude oil production to date with 4.4 million barrels of crude oil produced in Q3 2026, the highest monthly gross crude oil production to date with 1.5 million barrels of crude oil produced in August 2026, and the highest daily gross crude oil production to date with 52,479 barrels of crude oil produced in September 2026;
• In August 2026, the Company was the eighth largest producer of crude oil in North Dakota;
• Released rigs on 22 Bakken production wells, of which 19 were three-mile lateral wells, two were four-mile lateral wells, and one was a switchback well, which had an average lateral length of approximately 16,144 feet;
• Completed hydraulic fracturing on 15 wells, consisting of 11 four-mile lateral wells and 4 three-mile lateral wells, and placed 5 wells into production, including the Company’s first four-mile lateral switchback wells, which were the first such wells drilled in Montana;
• Received the first permits ever issued for five-mile lateral wells in the Williston Basin; and
• Produced approximately 14.2 million barrels of water and injected approximately 14.2 million barrels through the Company’s saltwater disposal wells, with approximately 99.5% of total produced water volumes handled internally through the Company’s operated facilities.

2026 Outlook

Based on results for the nine months ended September 30, 2026, and its expectations for the remainder of the year, the Company is updating its full-year 2026 outlook. The updated outlook below supersedes the outlook previously provided in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on March 17, 2026.

		As filed in Q3 2026 Form 10-Q												As filed in 2025 Form 10-K
		Year Ending December 31, 2026												Year Ending December 31, 2026
(dollars in thousands)				Lower Range						Upper Range						Lower Range					Upper Range
Revenue		$		1,610,000		(1)		$		1,780,000		(1)		$		1,190,000			$		1,490,000
Total operating expenses		$		1,060,000				$		1,120,000				$		965,000			$		1,030,000
Net income (loss)		$		(40,000	)	(2)		$		120,000		(2)		$		(40,000	)		$		65,000
EBITDA		$		525,000		(3)		$		695,000		(3)		$		475,000			$		605,000
Adjusted EBITDA		$		725,000		(3)		$		850,000		(3)		$	N/A				$	N/A
Total outstanding debt		$		2,090,000		(4)		$		2,230,000		(4)		$		1,900,000			$		2,150,000
Production:
Crude oil (Bbls)				13,100,000						13,700,000						12,500,000					13,600,000
Natural gas (Mcf)				17,500,000		(5)				18,200,000		(5)				14,900,000					16,300,000
NGL (Bbls)				1,550,000						1,640,000						475,000					520,000
Total (Boe) (6:1)				17,566,667						18,373,333						15,458,333					16,836,667
Average daily production (Boe/d) (6:1)				48,128						50,338						42,352					46,128

1. Based on an average benchmark commodity price of $88.39/Bbl for crude oil and $2.27/MMBtu for natural gas. Oil prices have been significantly volatile during 2026. Oil prices rose sharply in the first half of the year following the onset of the conflict in the Middle East involving Iran, Israel, the United States, and other countries in the region, reaching a high of $112.95 per Bbl on April 7, 2026. During the third quarter, oil prices ranged from a low of $69.60 per Bbl on July 6, 2026 to a high of $107.02 per Bbl on September 15, 2026, driven in part by renewed disruptions to shipping in the region.
2. Net income projections are subject to significant variability due to the accounting treatment of our derivative instruments. We use derivative instruments to manage exposure to commodity price volatility. These instruments are accounted for at fair value under GAAP, with changes in fair value recognized in earnings each reporting period. As a result, reported net income may be significantly impacted by unrealized gains or losses resulting from changes in forward commodity price curves related to future production periods, including 2026, 2027, 2028, and 2029. Our hedge positions currently result in derivative losses when crude oil prices rise. A substantial increase in forward crude oil prices, particularly late in the fourth quarter of 2026, would increase these losses before the higher prices are reflected in revenue, and could result in a net loss for the fourth quarter, which is reflected in the lower end of the net income (loss) range. Because these adjustments reflect changes in market expectations for future commodity prices rather than current operational performance, reported net income (loss) may fluctuate materially from period to period and may not be indicative of the Company’s underlying operating performance. Accordingly, deviations from projected net income (loss), EBITDA, or Adjusted EBITDA due primarily to non-cash mark-to-market adjustments on derivative instruments may occur even if operational performance remains consistent with expectations, and the Company may elect not to update previously issued net income (loss), EBITDA, or Adjusted EBITDA guidance when such deviations occur.
3. EBITDA and Adjusted EBITDA are non-GAAP financial measures. See “Non-GAAP Financial Measures” below for a reconciliation to net income (loss), the most directly comparable financial measure under GAAP. Assumes interest expense ranging between $240.0 million and $250.0 million and depreciation, depletion, and amortization expense ranging between $315.0 million and $335.0 million during the year ending December 31, 2026. We have not provided a full reconciliation of our forward outlook for EBITDA in reliance on the unreasonable efforts exception provided under Item 10(e)(1)(i)(B) of Regulation S-K. We are unable to predict with reasonable certainty the specific amount and timing of certain items required to provide a full reconciliation, in particular due to the impact that commodity prices can have on our derivative positions.
4. Assumes repayment of an aggregate of $148.0 million of debt outstanding as of December 31, 2025 and that matures prior to December 31, 2026, no prepayments of debt that is not maturing prior to December 31, 2026, and the issuance of between $708.1 million and $848.1 million of new debt during the year ending December 31, 2026.
5. Revenue from natural gas has not historically represented a significant portion of our total revenues. We anticipate this trend to continue and, as a result, we currently estimate 5,350,000 Mcf to 5,650,000 Mcf of natural gas volumes (of the production range presented above) will be sold and recognized as revenues for the year ending December 31, 2026.

Q3 2026 Quarter and Year to Date Financial Results

		Three Months Ended September 30,								Nine Months Ended September 30,
(in thousands)			2026				2025				2026				2025
Total revenues		$	460,385			$	189,021			$	1,164,916			$	468,602
Net income (loss)			(1,404	)			8,488				(35,538	)			32,785
EBITDA(1)			148,590				92,551				359,409				256,512
Adjusted EBITDA(1)			207,773				88,906				519,252				242,399
(1) EBITDA and Adjusted EBITDA are non-GAAP measures. See “Non-GAAP Financial Measures” below for a reconciliation to net income (loss), the most directly comparable financial measure under GAAP.

Net loss for the three months ended September 30, 2026 was $1.4 million, as compared to net income of $8.5 million for the same period in 2025. The year-over-year change was primarily due to an $89.9 million increase in loss on derivatives as a result of net cash settlements on matured contracts and unfavorable changes in the mark-to-market value of the Company’s outstanding commodity derivatives, a $43.2 million increase in depreciation, depletion, and amortization expense primarily due to increases in the Company’s depletable cost bases, a $38.2 million increase in cost of sales primarily associated with higher production volumes from the Company’s oil and gas operating activities, and a $22.8 million increase in interest expense, net, primarily due to increased interest costs associated with the Company’s term loan facility and the issuance of additional interest-bearing securities. These unfavorable variances were partially offset by a $144.5 million increase in product sales generated from the Company’s operated properties driven by additional wells placed into service, and a $35.6 million increase in mineral and royalty revenues primarily driven by a 35.1% increase in the average realized price for crude oil from $62.97/Bbl for the three months ended September 30, 2025 to $85.09/Bbl for the three months ended September 30, 2026, and a 51.0% and 30.3% increase in production volumes for crude oil and natural gas, respectively, from the Company’s acquisitions of mineral and non-operated working interests.

Net loss for the nine months ended September 30, 2026 was $35.5 million, as compared to net income of $32.8 million for the same period in 2025. The year-over-year change was primarily due to a $277.9 million increase in loss on derivatives as a result of net cash settlements on matured contracts and unfavorable changes in the mark-to-market value of the Company’s outstanding commodity derivatives, a $109.9 million increase in depreciation, depletion, and amortization expense primarily due to increases in the Company’s depletable cost bases, an $83.6 million increase in cost of sales primarily associated with higher production volumes from the Company’s oil and gas operating activities, and a $60.7 million increase in interest expense, net, primarily due to increased interest costs associated with the Company’s term loan facility and the issuance of additional interest-bearing securities. These unfavorable variances were partially offset by a $386.5 million increase in product sales generated from the Company’s operated properties driven by additional wells placed into service, and a $58.6 million increase in mineral and royalty revenues primarily driven by a 26.7% increase in the average realized price for crude oil from $65.36/Bbl for the nine months ended September 30, 2025 to $82.78/Bbl for the nine months ended September 30, 2026, and a 30.9% and 31.4% increase in production volumes for crude oil and natural gas, respectively, from the Company’s acquisitions of mineral and non-operated working interests.

Q3 2026 Quarter and Year to Date Operational Results

			Three Months Ended September 30,								Nine Months Ended September 30,
			2026				2025				2026				2025
Net oil-equivalent sales volumes (BOE)			4,229,601				2,550,211				11,248,689				6,477,302
Average daily sales volumes (BOE/d) (6:1)			45,974				27,720				41,204				23,726

• Average daily sales volume was 45,974 net Boe per day for the three months ended September 30, 2026, as compared to 27,720 net Boe per day for the same period in 2025, an increase of 65.9%. Average daily sales volume was 41,204 net Boe per day for the nine months ended September 30, 2026, as compared to 23,726 net Boe per day for the same period in 2025, an increase of 73.7%; and
• During the nine months ended September 30, 2026, the E&P operators of the Company’s properties, including PhoenixOp, drilled 445 gross and 53.6 net productive development wells on the acreage underlying the Company’s mineral and royalty interests, and the Company had 150 producing wells in service as of September 30, 2026, as compared to 78 producing wells in service as of September 30, 2025.

From Adam Ferrari, Chief Executive Officer

“We produced more oil this quarter than at any point in Phoenix Energy’s history. Revenue grew nearly two and a half times to $460 million, and we nearly doubled the number of producing wells in service. Our bottom line reflects hedging losses as oil prices rose, a natural result of the dynamics of today’s market. Our business remains as strong as ever.”

Phoenix Energy previously announced that it will hold a public earnings call on Wednesday, November 11, 2026 at 1:30 PM PT to review these results. Participants may access the webcast and presentation materials on the Company’s investor-relations website at https://phoenixenergy.com/investors/.

The Form 10-Q filing can be viewed in its entirety via the U.S. Securities and Exchange Commission’s EDGAR database or on Phoenix Energy’s website at https://phoenixenergy.com/investors/.

About Phoenix Energy

Phoenix Energy One, LLC, doing business as Phoenix Energy, is an energy company formed in 2019. The company is focused on oil and gas exploration and production across key U.S. basins, with a primary footprint in the Williston Basin of North Dakota and Montana. Phoenix Energy operates under a differentiated three-pronged strategy of direct drilling, royalty acquisition, and non-operated working interests. For more information on Phoenix Energy, please visit our website at https://phoenixenergy.com/.

Forward Looking Statements

This press release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995, which are statements regarding all matters that are not historical facts. Forward-looking statements may be identified using words such as “estimate,” “plan,” “project,” “forecast,” “intend,” “will,” “expect,” “anticipate,” “believe,” “seek,” “target” or other similar expressions that predict or indicate future events or trends or that are not statements of historical facts. Forward-looking statements in this release include, but are not limited to, our expectations regarding our financial position and financial and operating performance, including our outlook and guidance for 2026, our assumptions underlying such guidance, and the impact of commodity price volatility on our derivative instruments, as well as our expectations regarding improved operational efficiencies.

Forward-looking statements are based on Phoenix Energy’s beliefs, assumptions, and expectations, taking into account currently known market conditions and other factors. Phoenix Energy’s ability to predict results or the actual effect of future events, actions, plans, or strategies is inherently uncertain and involves certain risks and uncertainties, many of which are beyond its control. Phoenix Energy’s actual results and performance could differ materially from those set forth or anticipated in its forward-looking statements. You are cautioned that the forward-looking statements contained in this press release are not guarantees of future performance, and we cannot assure you that such statements will be realized or that the forward-looking events and circumstances will occur. All forward-looking statements in this press release are made only as of the date of this press release, based on information available to Phoenix Energy as of the date of this press release, and you are cautioned not to place undue reliance on forward-looking statements considering the risks and uncertainties associated with them.

Actual results may differ materially from these expectations due to changes in global, regional, or local economic, business, competitive, market, regulatory, and other factors, many of which are beyond our control. Management believes that these factors include but are not limited to the risk factors the Company has identified in its filings with the U.S. Securities and Exchange Commission, including in the section of its Annual Report on Form 10-K for the year ended December 31, 2025, under the heading “Risk Factors,” and subsequent Quarterly Reports on Form 10-Q. Risk factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. The Company may not actually achieve the plans, intentions or expectations disclosed in such forward-looking statements and you should not place undue reliance on the Company’s forward-looking statements. The Company undertakes no obligation to publicly update or revise any forward-looking statement, whether because of new information, future developments or otherwise, except as may be required by any applicable securities laws.

Non-GAAP Financial Measures

This press release contains “non-GAAP financial measures” that are financial measures that either exclude or include amounts that are not excluded or included in the most directly comparable measures calculated and presented in accordance with GAAP. Specifically, the Company presents “EBITDA” and “Adjusted EBITDA” as supplemental measures of financial performance that are not required by, or presented in accordance with, GAAP. The Company believes these measures can assist investors in comparing the Company’s operating performance across reporting periods on a consistent basis by excluding items that it does not believe are indicative of its core operating performance. Management believes these non-GAAP measures are useful in highlighting trends in the Company’s operating performance, while other measures can differ significantly depending on long term strategic decisions regarding capital structure, capital investments, etc. Management uses these non-GAAP measures to supplement GAAP measures of performance in the evaluation of the effectiveness of the Company’s business strategies and to make budgeting decisions. Management supplements GAAP results with non-GAAP financial measures to provide a more complete understanding of the factors and trends affecting the business than GAAP results alone provide. However, these measures should not be considered as alternatives to net income (loss) as a measure of financial performance or cash provided by operating activities as a measure of liquidity, or any other performance measure derived in accordance with GAAP. The presentation of these measures has limitations as analytical tools and should not be considered in isolation, or as a substitute for the Company’s results as reported under GAAP.

PHOENIX ENERGY ONE, LLC AND SUBSIDIARIES

Reconciliation of Non-GAAP Measures

The following table shows a reconciliation of EBITDA and Adjusted EBITDA to net income (loss), the most comparable GAAP measure, for the periods presented:

		Three Months Ended September 30,								Nine Months Ended September 30,
(in thousands)		2026				2025				2026				2025
Net income (loss)		$	(1,404	)		$	8,488			$	(35,538	)		$	32,785
Interest income			(324	)			(303	)			(712	)			(1,355	)
Interest expense, net			61,575				38,816				172,414				111,690
Depreciation, depletion, and amortization			88,743				45,550				223,245				113,392
EBITDA			148,590				92,551				359,409				256,512
Unrealized (gain) loss on derivatives			59,183				(3,645	)			159,843				(14,113	)
Adjusted EBITDA		$	207,773			$	88,906			$	519,252			$	242,399

Contact

Company: Phoenix Energy One, LLC

Email: InvestorRelations@phoenixenergy.com

Address: 18575 Jamboree Road, Suite 830, Irvine, CA 92612

Phone: 949-416-5037

• First survival data from EFTISARC-NEO, released in CTOS 2026 Abstract, demonstrate encouraging preliminary long-term outcomes in patients with resectable soft tissue sarcoma (STS).
• With a median follow-up of 19.1 months, 12-month disease-free survival (DFS), local recurrence-free survival (LRFS) and distant metastasis-free survival (DMFS) rates were 81.1%, 94.1% and 86.2%, respectively, in 38 evaluable patients.
• Investigators conclude that efti plus KEYTRUDA^® (pembrolizumab) and radiotherapy as neoadjuvant therapy showed promising preliminary long-term outcomes warranting registrationally relevant trials in patients with STS.
• Further and new analyses will be presented in a poster discussion session on 19 November 2026 and will be the subject of a further announcement by the Company.

SYDNEY, AUSTRALIA, Nov. 11, 2026 (GLOBE NEWSWIRE) — Immutep Limited (ASX: IMM; NASDAQ: IMMP) today announced the release of an abstract reporting interim disease-free survival data and clinicopathological correlates from EFTISARC-NEO, the investigator-initiated Phase II trial of eftilagimod alfa (efti) plus KEYTRUDA^® (pembrolizumab) and radiotherapy as neoadjuvant treatment for resectable soft tissue sarcoma (STS). Further detail and analyses will be presented in a poster discussion session on 19 November 2026 at the Connective Tissue Oncology Society (CTOS) 2026 Annual Meeting, being held from 18–21 November 2026 in Seoul, South Korea.

As reported in October 2025, EFTISARC-NEO has met its primary endpoint, with a median tumour hyalinisation/fibrosis of 51.5% in 38 evaluable patients, well above the pre-specified target of 35% and approximately 15% historically observed with radiotherapy alone.¹ Health-related quality of life data presented at the ESMO Congress 2026 in October showed no significant deterioration during treatment and a statistically significant improvement following surgery. The U.S. Food and Drug Administration granted Orphan Drug Designation to efti for the treatment of STS in April 2026. The survival outcomes reported here are secondary endpoints of the trial.

With a median follow-up of 19.1 months, the 12-month disease-free survival (DFS), local recurrence-free survival (LRFS) and distant metastasis-free survival (DMFS) rates were 81.1%, 94.1% and 86.2%, respectively, in 38 evaluable patients (data cut-off 30 April 2026). No differences in DFS were observed across tumour grade, stage or histological subtype.

The investigators concluded that efti plus pembrolizumab on top of standard radiotherapy as neoadjuvant therapy showed promising preliminary long-term outcomes warranting registrationally relevant trials in patients with STS. The investigators reported that high infiltration by tumour-infiltrating lymphocytes (TIL) and tumour hyalinisation/fibrosis after therapy may be associated with better DFS but that longer follow-up is necessary.

Follow-up for DFS and overall survival is ongoing.

For further details see the Events section of Immutep’s website. The poster with updated data will be made available on the Posters & Publications page of Immutep’s website at www.immutep.com following its presentation at the meeting.

About EFTISARC-NEO

EFTISARC-NEO is an investigator-initiated, open-label Phase II trial evaluating eftilagimod alfa in combination with KEYTRUDA^® (pembrolizumab) and radiotherapy as neoadjuvant treatment for patients with resectable soft tissue sarcoma. The trial is led by the Maria Skłodowska-Curie National Research Institute of Oncology in Warsaw, Poland, and is primarily funded by a grant from the Polish Medical Research Agency, with Immutep supplying efti. The primary endpoint is pathological response, measured as the percentage of tumour hyalinisation/fibrosis at resection. Secondary endpoints include safety, disease-free survival, local recurrence-free survival, distant metastasis-free survival, overall survival, radiological response and health-related quality of life. Forty patients were enrolled, with enrolment completed in January 2025 (ClinicalTrials.gov: NCT06128863).

About Eftilagimod Alfa (efti)

Eftilagimod alfa (efti) is Immutep’s proprietary soluble LAG-3 protein and MHC Class II agonist that activates antigen-presenting cells through the MHC Class II pathway, engaging both innate and adaptive immunity, including the priming of cytotoxic CD8+ T cells and the production of co-stimulatory signals and cytokines. Its favourable safety profile enables combination with anti-PD-(L)1 therapy, radiotherapy and/or chemotherapy. Efti has received Fast Track designation from the U.S. Food and Drug Administration in first-line head and neck squamous cell carcinoma and first-line non-small cell lung cancer, and Orphan Drug Designation in soft tissue sarcoma.

About Immutep

Immutep is a clinical-stage biotechnology company developing novel immunotherapies for cancer and autoimmune disease. The Company is a pioneer in the understanding and advancement of therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), and its diversified product portfolio harnesses LAG-3’s ability to stimulate or suppress the immune response. Immutep is dedicated to leveraging its expertise to bring innovative treatment options to patients in need and to maximise value for shareholders. For more information, please visit www.immutep.com.

Forward-Looking Statements

This press release contains forward-looking statements, including statements regarding anticipated clinical development, regulatory progress and potential benefits of eftilagimod alfa. These forward-looking statements are based on current expectations, estimates and projections, and involve known and unknown risks, uncertainties and other important factors that could cause actual results to differ materially from those expressed or implied in such statements.

Factors that could cause actual results to differ materially include risks associated with clinical trial outcomes, regulatory developments, and the Company’s ability to advance its product candidates.

Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date of this release. Immutep undertakes no obligation to update or revise such statements, except as required by applicable law.

Disclaimer

This announcement has been prepared for informational purposes only and does not constitute an offer to sell, or a solicitation of an offer to buy, securities in any jurisdiction.

KEYTRUDA^® is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.

¹ Schaefer IM, Hornick JL, Barysauskas CM, Raut CP, Patel SA, Royce TJ, Fletcher CDM, Baldini EH. Histologic Appearance After Preoperative Radiation Therapy for Soft Tissue Sarcoma: Assessment of the European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group Response Score. Int J Radiat Oncol Biol Phys. 2017 Jun 1;98(2):375-383.

Australian Investors/Media:
Eleanor Pearson, Sodali & Co.
+61 2 9066 4071; eleanor.pearson@sodali.com

US Investors/Media:
Matthew Beck, astr partners
+1 (917) 415-1750; matthew.beck@astrpartners.com

HOUSTON, Nov. 10, 2026 (GLOBE NEWSWIRE) — Epsilon Energy Ltd. (“Epsilon” or the “Company”) (NASDAQ: EPSN) today announced that it will issue its third quarter 2026 earnings release on Monday, November 23, 2026 after the market close and host a conference call to discuss its financial and operating results on Tuesday, November 24, 2026 at 10:00 a.m. Central Time (11:00 a.m. Eastern Time).

Interested parties in the United States and Canada may participate toll-free by dialing (833) 816-1385. International parties may participate by dialing (412) 317-0478. Participants should ask to be joined to the “Epsilon Energy Third Quarter 2026 Earnings Conference Call.”

A webcast can be viewed at: https://event.choruscall.com/mediaframe/webcast.html?webcastid=ZeZjRfnX. A webcast replay will be available on the Company’s website (www.epsilonenergyltd.com) following the call.

About Epsilon

Epsilon Energy Ltd. is a North American onshore natural gas and oil production and gathering company with assets across the Appalachian, Powder River, Permian, and Western Canadian Sedimentary basins.

Contact Information:

281-670-0002

Jason Stabell
Chief Executive Officer
Jason.Stabell@EpsilonEnergyLTD.com

Andrew Williamson
Chief Financial Officer
Andrew.Williamson@EpsilonEnergyLTD.com

Product developed and manufactured by MediPharm Labs is now available by prescription through Brazilian pharmacies

TORONTO, Nov. 10, 2026 (GLOBE NEWSWIRE) — MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) (“MediPharm”, “MediPharm Labs” or the “Company”), is pleased to announce the commercial launch of a full-spectrum CBD oral oil in Brazil through its pharmaceutical partner, Alko do Brasil Indústria e Comércio Ltda, “Alko”.

MediPharm manufactures the product at its pharmaceutical facility in Barrie, Ontario, which holds ANVISA Good Manufacturing Practices (“GMP”) certification. Alko do Brasil obtained the Sanitary Authorization based on a comprehensive regulatory dossier submitted to ANVISA, with technical and regulatory support from MediPharm Labs, resulting in authorization of the product for medicinal use in Brazil.

Brazil remains one of the world’s most highly regulated cannabinoid markets, requiring foreign manufacturers to comply with applicable ANVISA regulatory requirements and GMP standards and to provide comprehensive documentation related to product quality, stability, manufacturing, regulatory compliance and post-market obligations.

“This launch represents the continued execution of MediPharm’s international growth strategy and further validates our position as a trusted global supplier of cannabinoid-based products manufactured under pharmaceutical quality standards,” said Greg Hunter, Chief Executive Officer of MediPharm Labs.

“Brazil is one of the fastest-growing medical cannabis markets in the world, but it is also one of the most difficult to access from a regulatory perspective. Successfully supporting an ANVISA Sanitary Authorization demonstrates the strength of our pharmaceutical manufacturing capabilities, regulatory expertise and commitment to quality. We are proud to have worked closely with Alko throughout the authorization process and are pleased that patients across Brazil can now access an ANVISA-authorized Cannabis Product manufactured at our GMP-certified facility.”

Brazil is widely regarded as an attractive long-term medical cannabis market. The market has grown rapidly following implementation of ANVISA’s cannabis framework in 2019 and continues to be driven by increasing medical interest and demand for regulated Cannabis Products. Kaya Mind estimates the potential size of Brazil’s medical cannabis market at approximately C$2.58 billion.¹ Under Brazil’s regulatory framework applicable to ANVISA-authorized Cannabis Products, commercialization is focused on pharmaceutical dosage forms rather than dried Cannabis flower, including products such as oils, oral formulations and other dosage forms that meet applicable ANVISA regulatory requirements.

“Alko has seized the opportunity and sees a bright future for their investment in Brazilian cannabis. From the beginning, our objective has been to expand access in Brazil to quality-controlled Cannabis Products manufactured in accordance with the applicable regulatory requirements. MediPharm’s manufacturing capabilities, ANVISA GMP-certified facility and technical expertise were important throughout the regulatory process. We are pleased to make this ANVISA-authorized Cannabis Product available in Brazil through the legally established prescription and pharmacy dispensing channels,” says Alko’s Co-CEO Juliana Komel

MediPharm believes its pharmaceutical manufacturing platform is well positioned to support growth in Brazil. MediPharm is one of a limited number of international cannabinoid manufacturers with the regulatory infrastructure and pharmaceutical manufacturing capabilities necessary to support commercialization in Brazil.

About MediPharm Labs

Founded in 2015, MediPharm Labs specializes in the development and manufacture of purified, pharmaceutical-quality cannabis concentrates, active pharmaceutical ingredients (API) and advanced derivative products utilizing a Good Manufacturing Practices certified facility with ISO standard-built clean rooms.

In 2021, Health Canada issued MediPharm Labs a Pharmaceutical Drug Establishment Licence, making it the first cannabis company in North America to hold a commercial-scale domestic Good Manufacturing Practices licence for extracting multiple natural cannabinoids. MediPharm maintains international GMP certifications, including EU-GMP certification, ANVISA GMP certification from Brazil and compliance with Australia’s Therapeutic Goods Administration requirements.

The Company develops, formulates, processes, packages and distributes cannabis and advanced cannabinoid-based products to domestic and international medical markets.

Website: www.medipharmlabs.com

About Alko do Brasil

Committed to innovation, operational excellence, and the long-term sustainability of the healthcare sector, ALKO is dedicated to becoming a leading Brazilian platform for introducing, commercializing, and expanding specialized therapies. Through strategic partnerships, regulatory expertise, and a patient-centred approach, the Company seeks to advance access to innovative treatment options and contribute meaningfully to improved health outcomes and quality of life for patients throughout Brazil.

For Further Information, Please Contact:

MediPharm Labs Investor Relations
Telephone: +1 416.913.7425
Email: investors@medipharmlabs.com
Website: www.medipharmlabs.com

¹ Kaya Mind Dados e Pesquisas Ltda., Anuário da Cannabis Medicinal 2024, p. 28. The report identifies a potential Brazilian medical cannabis market of R$9,485,511,604, excluding transversal conditions such as pain, stress and sleep disorders. Converted to approximately C$2.58 billion using an exchange rate of C$0.2718 per Brazilian real on September 29, 2026. The underlying market estimate was originally attributed by Kaya to its 2021 market analysis and reproduced in the 2024 yearbook. Foreign exchange rates fluctuate, and the Canadian-dollar value is presented for reference only.

Cautionary Note Regarding Forward-Looking Information

This news release contains “forward-looking information” and “forward-looking statements” within the meaning of applicable Canadian securities legislation. Forward-looking statements in this news release include, among other things, statements relating to the anticipated commercial success of the product in Brazil, future patient access, the potential size and future growth of the Brazilian medical cannabis market, the Company’s ability to expand its Brazilian business, expected demand for pharmaceutical-grade cannabinoid products, and MediPharm’s ability to continue supporting regulated international markets. Forward-looking statements are based on management’s current expectations and assumptions and are subject to known and unknown risks and uncertainties that may cause actual results to differ materially from those expressed or implied by such statements. Readers should not place undue reliance on forward-looking statements. MediPharm assumes no obligation to update forward-looking statements except as required by applicable law.

Successful TuneIn integration and rapid FAST channel expansion drive Adjusted EBITDA up 47.5%

• Organic growth of 15.1% year-over-year in Broadcast and Recurring Commercial Music Revenues;
• Revenues increased 51.3% to $171.4 million in the second quarter of 2027 from $113.3 million in the second quarter of 2026;
• Adjusted EBITDA⁽¹⁾ grew 47.5% to $58.3 million in the second quarter of 2027 from $39.5 million in the same period last year. Adjusted EBITDA⁽¹⁾ by segment was $49.9 million or 36.4% of revenues for Broadcasting and Commercial Music, $10.8 million or 31.8% of revenues for Radio, and $(2.4) million for Corporate;
• Net income appreciated to $16.2 million, or $0.24 per diluted share, in the second quarter of 2027 compared to $11.8 million, or $0.17 per diluted share, in the second quarter of 2026;
• Adjusted Net income⁽¹⁾ improved 58.8% to $34.7 million, or $0.51 per diluted share, in the second quarter of 2027 from $21.9 million, or $0.32 per diluted share, in the same period of 2026;
• Cash flow from operating activities increased 81.9% to $44.3 million, or $0.65 per diluted share, in the second quarter of 2027 from $24.3 million, or $0.35 per diluted share, in the second quarter of 2026;
• Adjusted free cash flow⁽¹⁾ grew to $39.0 million, or $0.57 per diluted share, in the second quarter of 2027 compared to $28.4 million, or $0.41 per diluted share, in the same period of 2026; and
• Net debt to Pro Forma Adjusted EBITDA⁽¹⁾ ratio reached 2.39x in the second quarter of 2027 compared to 2.13x in the second quarter of 2026.

MONTREAL, Nov. 10, 2026 (GLOBE NEWSWIRE) — Stingray Group Inc. (TSX: RAY) (the “Corporation”; “Stingray”), the world’s leading connected streaming media company, announced today its financial results for the second quarter of fiscal 2027 ended September 30, 2026.

Financial Highlights (in thousands of dollars, except per share data)	Three months ended September 30
	Q2-2027	Q2-2026	%
Revenues	171,392	113,262	51.3
Adjusted EBITDA(1)	58,311	39,520	47.5
Net income	16,209	11,772	37.7
Per share – diluted ($)	0.24	0.17	41.2
Adjusted Net income(1)	34,749	21,884	58.8
Per share – diluted ($)	0.51	0.32	59.4
Cash flow from operating activities	44,254	24,329	81.9
Adjusted free cash flow(1)	39,020	28,396	37.4

(1)

This is a non-IFRS measure and is not a standardized financial measure. The Corporation’s method of calculating financial measures may differ from the methods used by other issuers and, accordingly, the definition of these non-IFRS financial measures may not be comparable to similar measures presented by other issuers. Refer to “Non-IFRS Measures” on page 5 of this news release for more information about each non-IFRS measure and pages 6-7 for the reconciliations to the most directly comparable IFRS financial measures.

Reporting on second quarter results, Stingray’s President, co-founder and CEO Eric Boyko stated:

“Stingray’s strong second quarter results reflect the team’s outstanding effort to deliver higher profitability across all our growing segments. Stingray’s Adjusted EBITDA increased 47.5% year over year to $58.3 million in the second quarter. We are pleased to have achieved an Adjusted EBITDA margin of 34.0%, bringing us closer to our annual target of 35%.

“Since completing the TuneIn acquisition, we have focused on integrating the business and realizing revenue and cost synergies. These synergies have reached an annualized run rate of $45 million and $12 million, respectively, exceeding our internal expectations. We believe there are further opportunities to optimize our synergies both in terms of revenues and costs moving forward.

“Our FAST channel segment delivered revenue growth of more than 85% year over year. During the quarter, we secured the rights to monetize Samsung’s unsold advertising inventory, making Samsung the third major television manufacturer to join Stingray’s Premium Ad Network.

“We also expanded our FAST channel distribution in Europe and the Middle East, launching 20 channels across 13 European countries on LG Smart TVs, a new suite of channels in the United Arab Emirates on LG Channels, and 17 channels across nine countries on Rakuten TV. In addition, we continued to deploy our popular products such as Moodscape and continued to expand our offering and distribution. We continue to see mid to long term growth opportunities in the Connected TV and FAST channel vertical.

“In-car entertainment revenue grew at a double-digit rate in the second quarter. We recently announced Ford Streaming Radio and Lincoln Streaming Radio, co-branded applications powered by Stingray that are rolling out in select North American vehicles. Their audio catalogue includes more than 100 curated, ad-free music channels, 100,000 local and international radio stations, and four million podcasts across a range of topics. We also entered into an agreement with Stellantis to bring the TuneIn app to select future vehicles.

“Broadcasting and Commercial Music revenue surged nearly 70% year over year to $137.3 million in the second quarter. This outstanding growth reflects Stingray’s strong position in distribution and our proven ability to monetize an expanding advertising inventory, driven by robust demand across our Premium Ad Network and further amplified by TuneIn. Advertising revenue—which includes TuneIn, FAST channels and Retail Media—more than doubled during the same period, while organic sales increased 15%. Finally, as expected, Radio revenue climbed 5% to $34.1 million, supported by higher national airtime and digital revenue,” Mr. Boyko concluded.

Second Quarter Results
Revenues increased $58.1 million, or 51.3%, to $171.4 million in the second quarter of 2027 from $113.3 million in the second quarter of 2026. The year-over-year growth was mainly driven by higher advertising revenues from the TuneIn acquisition, increased FAST channel sales and a positive foreign exchange impact.

Revenues in Canada decreased $1.1 million, or 2.1%, to $50.4 million in the second quarter of 2027 from $51.5 million in the same period of 2026. This decrease reflects a normalization of equipment and installation sales related to digital signage, following an exceptionally strong performance in the prior year.

Revenues in the United States grew $57.0 million, or 109.9%, to $109.0 million in the second quarter of 2027 from $52.0 million in the second quarter of 2026. The increase was primarily due to higher advertising revenues from the TuneIn acquisition and greater FAST channel sales.

Revenues in Other countries improved $2.2 million, or 21.7%, to $12.0 million in the second quarter of 2027 from $9.8 million in the same period of 2026 on the strength of greater FAST channel sales.

Broadcasting and Commercial Music revenues increased $56.4 million, or 69.8%, to $137.3 million in the second quarter of 2027 from $80.9 million in the second quarter of 2026. The growth was primarily driven by higher advertising revenues from the TuneIn acquisition and greater FAST channel sales. For the second quarter of 2027, Radio revenues improved $1.7 million, or 5.3%, to $34.1 million from $32.4 million in the same period of 2026. This increase was mainly due to higher national airtime and digital revenues.

Consolidated Adjusted EBITDA grew $18.8 million, or 47.5%, to $58.3 million in the second quarter of 2027 from $39.5 million in the second quarter of 2026. Adjusted EBITDA margin reached 34.0% in the second quarter of 2027 compared to 34.9% in the same period last year. The increase in Adjusted EBITDA year-over-year can mainly be attributed to TuneIn and overall revenue growth. The decline in Adjusted EBITDA margin was largely due to lower gross margins related to the acquired TuneIn and The Singing Machine product offerings, combined with a shift in product mix.

For the second quarter of 2027, net income totaled $16.2 million, or $0.24 per diluted share, compared to $11.8 million, or $0.17 per diluted share, in the second quarter of 2026. The increase was primarily due to improved operating results and an unrealized gain on the fair value of derivative financial instruments in the most recent quarter. These factors were partially offset by higher acquisition costs and increased amortization of intangible assets related to the TuneIn acquisition, along with a higher income tax expense.

Cash flow from operating activities amounted to $44.3 million in the second quarter of 2027 compared to $24.3 million in the second quarter of 2026. The increase was mostly due to improved operating results and a positive change in non-cash working capital items in the most recent quarter. These factors were partially offset by higher acquisition costs related to the TuneIn acquisition.

Adjusted free cash flow in the second quarter of 2027 totaled $39.0 million compared to $28.4 million in the same period of 2026. The increase can largely be attributed to improved operating results.

As of September 30, 2026, Stingray had cash and cash equivalents of $19.7 million and credit facilities of $548.9 million.

Declaration of Dividend
On November 10, 2026, Stingray declared a dividend of $0.100 per subordinate voting share, variable subordinate voting share and multiple voting share, a $0.015 increase over its previous disbursement. This increase reflects our continued confidence in our execution to drive long-term growth and value creation. The dividend will be payable on or around December 15, 2026, to shareholders on record as of November 30, 2026.

The Corporation’s dividend policy is at the discretion of the Board of Directors and may vary depending upon, among other things, our available cash flow, results of operations, financial condition, business growth opportunities and other factors that the Board of Directors may deem relevant.

The dividends paid are designated as “eligible” dividends for the purposes of the Income Tax Act (Canada) and any corresponding provisions of provincial and territorial tax legislation.

Renewal of Normal Course Issuer Bid
On September 22, 2026, Stingray renewed its normal course issuer bid (NCIB) with the Toronto Stock Exchange, obtaining authorization to repurchase up to 4.4 million subordinate voting shares and variable subordinate voting shares over a 12-month period extending until September 26, 2027. The shares represent approximately 10% of the Corporation’s public float. In accordance with TSX requirements, Stingray is entitled to purchase on any trading day up to 9,914 shares which represent 25% of its average daily trading volume.

Business Highlights and Subsequent Events

• On November 5, 2026, the Corporation announced the expansion of its partnership with LG to launch a suite of FAST channels and Moodscapes on LG Channels in the United Arab Emirates, bringing a diverse selection of curated audio and video content to LG Smart TV users in the region.
• On October 21, 2026, the Corporation announced the expansion of TuneIn’s news lineup with the addition of all eight ABC Owned Television Stations FAST channels, bringing local news, weather, and Localish programming from major U.S. markets, including New York, Los Angeles, Chicago, and Philadelphia, to listeners across more than 200 connected devices and vehicle integrations. 
• On October 20, 2026, the Corporation announced that Stingray Music+, its comprehensive audio entertainment app, is now available for automakers to select through HARMAN Ready Link Marketplace, enabling automakers to offer drivers and passengers access to a wide range of premium audio content directly through their in-vehicle infotainment systems.
• On October 19, 2026, the Corporation announced the launch of the Ford Streaming Radio and Lincoln Streaming Radio apps. Powered by Stingray, these new cobranded applications are rolling out now, bringing a wealth of audio entertainment directly to the dashboard of select Ford and Lincoln vehicles.
• On September 24, 2026, the Corporation announced that TuneIn has entered into an agreement with Stellantis, a leading global automaker, to bring the TuneIn application, with its expansive catalog of radio stations and podcasts, directly into select future Stellantis vehicles.
• On September 15, 2026, the Corporation announced the launch of a new ad-supported version of its popular Stingray Karaoke service in partnership with Gameloft, a leader in the creation and publishing of games. This successful cooperation was made possible through the commercial support and expertise of BACSTAGE. The service is now available globally on Gameloft’s LudiGames portal, and is also accessible through Samsung Instant Play, Xiaomi Game Center, and Microsoft Start.
• On September 10, 2026, the Corporation announced the launch of 17 localized FAST music channels on Rakuten TV, a leading streaming platform in Europe, providing viewers with a deeply customized audio experience. The new Stingray Music channels are currently available to audiences in France, Germany, Italy, the Netherlands, Poland, Portugal, Spain, Sweden, and the UK. 
• On August 11, 2026, the Corporation announced a significant expansion of its European presence through a new agreement with LG. Starting in October, Stingray will launch 20 FAST channels on LG Channels, available to LG Smart TV owners across 13 European countries. This expansive rollout brings a diverse and highly curated selection of music, concert, and lifestyle programming directly to the living rooms of LG TV owners. The lineup features a mix of broadly appealing content and highly localized programming tailored to regional tastes.
• On August 11, 2026, the Corporation announced a new partnership with iM Media Labs to bring TuneIn to the iM Media Hub, a unified, vehicle-native media platform that integrates radio, streaming, podcasts and more for connected vehicles. The integration enables drivers to access TuneIn’s live sports, news, music, podcasts and radio through a native, OEM-branded in-vehicle experience, without requiring phone projection.
• On July 29, 2026, the Corporation announced the launch of the Just For Laughs Stand-up channel on Samsung TV Plus in Australia and New Zealand.
• On July 27, 2026, the Corporation announced that Stingray Radio completed its acquisition of CHUP-FM (C97.7) in Calgary from Rawlco Radio Ltd. The acquisition was first announced in November 2025 and received approval from the Canadian Radio-television and Telecommunications Commission (CRTC) in June 2026.
• On July 15, 2026, the Corporation partnered with Telly to bring Stingray’s karaoke and music apps to the industry’s first 55-inch 4K dual-screen smart TV. Through the partnership, Stingray Karaoke and Stingray Streams are now available for free on Telly in the United States, giving users entirely new ways to transform the biggest screen in the home into an interactive entertainment experience.
• On July 15, 2026, the Corporation announced that TuneIn will be integrated into Bragi’s Audio Apps Space. Through a new partnership, TuneIn will expand its availability across Bragi’s growing ecosystem of more than 20 million smart headphones, delivering a smarter, more intuitive way for listeners to access live radio, sports, news, music, and podcasts.

Conference Call
The Corporation will hold a conference call tomorrow, November 11, 10:00 AM (ET), to review its financial results. Interested parties can join the call by dialing 1-800-717-1738 (toll free), Montreal (+1) 514-400-3792, (+1) 289-514-5100 (Toronto) or 1-646-517-3975 (New York). A rebroadcast of the conference call will be available until December 31, 2026, 11:59 p.m. Eastern time, by dialing (+1) 888-660-6264, Toronto (+1) 289-819-1325 or New York (+1) 646-517-3975 and entering passcode 71595.

About Stingray
Stingray Group Inc. (TSX:RAY), the world’s leading connected streaming media company, delivers the best curated audio and video content to consumers worldwide. As a pioneer in multiplatform streaming and distribution, Stingray’s vast digital content portfolio includes thousands of live audio and radio stations, premium music channels, concerts and music documentaries, karaoke products, as well as ambience and wellness channels. Its offering is distributed via connected TVs, smart speakers, mobile, connected cars and retail. Reaching hundreds of millions of consumers every month, Stingray’s products offer an unparalleled advertising reach, enabling brands to connect with an engaged audience across the world.

Home to globally renowned brands such as TuneIn, Singing Machine, Stingray Karaoke and Qello Concerts, Stingray is powered by a worldwide team of more than 1,000 employees. For more information, visit www.stingray.com. 

Forward-Looking Information
This news release contains forward-looking information within the meaning of applicable Canadian securities law. Such forward-looking information includes, but is not limited to, information with respect to Stingray’s goals, beliefs, plans, expectations, anticipations, estimates and intentions. Forward-looking information is identified by the use of terms and phrases such as “may”, “would”, “should”, “could”, “expect”, “intend”, “estimate”, “anticipate”, “plan”, “foresee”, “believe”, and “continue”, or the negative of these terms and similar terminology, including references to assumptions. Please note, however, that not all forward-looking information contains these terms and phrases. Forward-looking information is based upon a number of assumptions and is subject to a number of risks and uncertainties, many of which are beyond Stingray’s control. These risks and uncertainties could cause actual results to differ materially from those that are disclosed in or implied by such forward-looking information.

These risks and uncertainties include, but are not limited to, the risk factors identified in Stingray’s Annual Information Form for the year ended March 31, 2026, which is available on SEDAR+ at www.sedarplus.ca. Consequently, all of the forward-looking information contained herein is qualified by the foregoing cautionary statements, and there can be no guarantee that the results or developments that Stingray anticipates will be realized or, even if substantially realized, that they will have the expected consequences or effects on Stingray’s business, financial condition or results of operations. Unless otherwise noted or the context otherwise indicates, the forward-looking information contained herein is provided as of the date hereof, and Stingray does not undertake to update or amend such forward-looking information whether as a result of new information, future events or otherwise, except as may be required by applicable law.

Non-IFRS Measures
The Corporation believes that Adjusted EBITDA and Adjusted EBITDA margin are important measures when analyzing its operating profitability without being influenced by financing decisions, non-cash items and income tax strategies. Comparison with peers is also easier as companies rarely have the same capital and financing structure. The Corporation believes that Adjusted Net income and Adjusted Net income per share are important measures as it shows stable results from its operation which allows users of the financial statements to better assess the trend in the profitability of the business. The Corporation believes that Adjusted free cash flow and Adjusted free cash flow per share are important measures when assessing the amount of cash generated after accounting for capital expenditures and non-core charges. It demonstrates cash available to make business acquisitions, pay dividends and reduce debt. The Corporation believes that Net debt and Net debt to Pro Forma Adjusted EBITDA are important to analyse the company’s debt repayment capacity on an annualized basis, taking into consideration the annualized adjusted EBITDA of acquisitions made during the last twelve months.

Each of these non-IFRS financial measures is not an earnings or cash flow measure recognized by International Financial Reporting Standards (IFRS) and does not have a standardized meaning prescribed by IFRS. This method of calculating such financial measures may differ from the methods used by other issuers and, accordingly, our definition of these non-IFRS financial measures may not be comparable to similar measures presented by other issuers.
Investors are cautioned that non-IFRS financial measures should not be construed as an alternative to net income determined in accordance with IFRS as indicators of our performance or to cash flows from operating activities as measures of liquidity and cash flows.

Reconciliation of Net income to Adjusted EBITDA, Adjusted Net income, LTM Adjusted EBITDA and Pro Forma Adjusted EBITDA

	3 months					6 months
(in thousands of Canadian dollars)	Sept. 30, 2026 Q2 2027		Sept. 30, 2025 Q2 2026			Sept. 30, 2026 YTD 2027		Sept. 30, 2025 YTD 2026
Net income	16,209		11,772			22,799		28,555
Net finance expense (income)	1,470		9,282			13,198		6,528
Change in fair value of investments	1		(15	)		(7	)	22
Income taxes	7,126		3,906			8,348		9,798
Depreciation and write-off of property and equipment	1,880		1,977			3,653		3,793
Depreciation of right-of-use assets	1,342		1,091			2,703		2,239
Amortization of intangible assets	12,158		4,207			24,704		8,765
Share-based compensation	266		177			555		(93	)
Performance and deferred share unit expense	4,300		4,214			7,647		8,346
Share of results of investments in associates	60		73			(95	)	373
Loss (gain) on disposals	–		4			(8	)	503
Acquisition, legal, restructuring and other expenses	13,499		2,832			25,066		4,347
Adjusted EBITDA	58,311		39,520			108,563		73,176
Adjusted EBITDA margin	34.0	%	34.9	%		33.0	%	35.0	%
Net income	16,209		11,772			22,799		28,555
Adjusted for:
Unrealized loss (gain) of derivative instruments	(5,060	)	2,350			(3,677	)	(2,185	)
Amortization of intangible assets	12,158		4,207			24,704		8,765
Change in fair value of investments	1		(15	)		(7	)	22
Share-based compensation	266		177			555		(93	)
Performance and deferred share unit expense	4,300		4,214			7,647		8,346
Share of results of investments in associates	60		73			(95	)	373
Loss (gain) on disposals	–		4			(8	)	503
Acquisition, legal, restructuring and other expenses	13,499		2,832			25,066		4,347
Income taxes related to above noted adjustments	(6,684	)	(3,730	)		(14,288	)	(5,438	)
Adjusted Net income	34,749		21,884			62,696		43,195
Average number of shares outstanding (diluted)	68,022		68,628			68,454		68,625
Adjusted Net income per share (diluted)	0.51		0.32			0.92		0.63

(in thousands of Canadian dollars)	September 30, 2026		September 30, 2025		March 31, 2026
LTM Adjusted EBITDA	195,573		150,311		160,186
Permanent cost-saving initiatives	810		489		940
Cost synergies from the acquisition of TuneIn	6,012		–		9,813
Adjusted EBITDA for the months prior to the business acquisitions which are not already reflected in the results	18,783		–		40,613
Pro Forma Adjusted EBITDA	221,178		150,800		211,552

Reconciliation of Cash Flow From Operating Activities to Adjusted Free Cash Flow

	3 months					6 months
(in thousands of Canadian dollars)	Sept. 30, 2026 Q2 2027		Sept. 30, 2025 Q2 2026			Sept. 30, 2026 YTD 2027		Sept. 30, 2025 YTD 2026
Cash flow from operating activities	44,254		24,329			49,055		43,316
Add / Less:
Acquisition of property and equipment	(1,487	)	(2,171	)		(3,006	)	(4,324	)
Acquisition of intangible assets other than internally developed intangible assets	(240	)	(262	)		(630	)	(598	)
Addition to internally developed intangible assets	(3,402	)	(1,307	)		(6,419	)	(2,701	)
Interest paid	(7,654	)	(4,830	)		(15,467	)	(9,785	)
Repayment of lease liabilities	(1,510	)	(1,415	)		(2,752	)	(2,282	)
Net change in non-cash operating working capital items	(4,485	)	9,709			23,819		19,464
Unrealized loss (gain) on foreign exchange	45		1,511			1,833		(244	)
Acquisition, legal, restructuring and other expenses	13,499		2,832			25,066		4,347
Adjusted free cash flow	39,020		28,396			71,499		47,193

Calculation of Net Debt and Net Debt to Pro Forma Adjusted EBITDA Ratio

(in thousands of Canadian dollars)	September 30, 2026		September 30, 2025		March 31, 2026
Credit facilities	548,919		336,273		524,106
Subordinated debt	–		–		–
Cash and cash equivalents	(19,718	)	(15,145	)	(20,747	)
Net debt	529,201		321,128		503,359
Net debt to Pro Forma Adjusted EBITDA	2.39		2.13		2.38

Note to readers: Consolidated financial statements and Management’s Discussion & Analysis of Operating Results and Financial Position are available on the Corporation’s website at www.corporate.stingray.com and on SEDAR+ at www.sedarplus.ca.

Contact Information
Mathieu Péloquin
Senior Vice-President, Marketing and Communications
Stingray
(514) 664-1244, ext. 2362
mpeloquin@stingray.com

Company Announcement

COPENHAGEN, Denmark; November 10, 2026 – Genmab A/S (Nasdaq: GMAB) – In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, this document discloses the data of the transactions made in Genmab A/S (Nasdaq: GMAB) by managerial employees and their closely associated persons.

The company’s managerial employees and their closely associated persons have given Genmab A/S power of attorney on their behalf to publish trading in Genmab shares by the company’s managerial employees and their closely associated persons.

About Genmab 
Genmab is an international biotechnology company dedicated to improving the lives of people with cancer and other serious diseases through innovative antibody medicines. For over 25 years, its passionate, innovative and collaborative team has advanced a broad range of antibody-based therapeutic formats, including bispecific antibodies, antibody–drug conjugates (ADCs), immune-modulating antibodies and other next-generation modalities. Genmab’s science powers eight approved antibody medicines, and the company is advancing a strong late-stage clinical pipeline, including wholly owned programs, with the goal of delivering transformative medicines to patients.

Established in 1999, Genmab is headquartered in Copenhagen, Denmark, with international presence across North America, Europe and Asia Pacific. For more information, please visit Genmab.com and follow us on LinkedIn, X, Facebook and Instagram.

Contact: 
Marisol Peron, Senior Vice President, Global Communications & Corporate Affairs
T: +1 609 524 0065; E: mmp@genmab.com

Andrew Carlsen, Vice President, Head of Investor Relations
T: +45 3377 9558; E: acn@genmab.com

The Company Announcement contains forward looking statements. The words “believe,” “expect,” “anticipate,” “intend” and “plan” and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with preclinical and clinical development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products or technologies obsolete, and other factors. For a further discussion of these risks, please refer to the risk management sections in Genmab’s most recent financial reports, which are available on www.genmab.com and the risk factors included in Genmab’s most recent Annual Report on Form 20-F and other filings with the U.S. Securities and Exchange Commission (SEC), which are available at www.sec.gov. Genmab does not undertake any obligation to update or revise forward looking statements in the Company Announcement nor to confirm such statements to reflect subsequent events or circumstances after the date made or in relation to actual results, unless required by law.

Genmab A/S and/or its subsidiaries own the following trademarks: Genmab^®; the Y-shaped Genmab logo^®; Genmab in combination with the Y-shaped Genmab logo^®; HuMax^®; DuoBody^®; HexaBody^®; DuoHexaBody^®, HexElect^® and KYSO^®.

CVR no. 2102 3884
LEI Code 529900MTJPDPE4MHJ122

Genmab A/S
Carl Jacobsens Vej 30
2500 Valby
Denmark

Attachment

• 101126_CA47_Managerial Employee Transactions

NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES 

HALIFAX, Nova Scotia, Nov. 10, 2026 (GLOBE NEWSWIRE) — NOVA LEAP HEALTH CORP. (TSXV: NLH) (“Nova Leap” or “the Company”), a growing provider of home-based and community care services in North America, is pleased to announce the release of financial results for the quarter ended September 30, 2026. All amounts are in United States dollars unless otherwise specified.

Nova Leap Q3 2026 Financial Results

Financial results for the quarter ended September 30, 2026 include the following:

• Q3 2026 revenue of $9,531,140 was the highest in the Company’s history and increased by 15.3% relative to Q3 2025 revenue of $8,264,326.
• Trailing twelve-month revenues for the period from October 1, 2025 to September 30, 2026 were $34,864,119, the highest for any twelve-month period in the Company’s history.
• The Company achieved organic revenue growth of 8.2% in Q3 2026 over Q3 2025.

• Q3 2026 Adjusted EBITDA of $860,804 was an increase of 28.3% over Q3 2025 Adjusted EBITDA of $670,706 (see calculation of Adjusted EBITDA below).
• Trailing twelve-month Adjusted EBITDA for the period from October 1, 2025 to September 30, 2026 was $2,785,448, the highest for any twelve-month period in the Company’s history.

• Gross profit margin as a percentage of revenue remained strong at 39.9% in Q3 2026. Gross profit margin percentage was 39.6% in Q3 2025.
• The Company generated income from operating activities in Q3 2026 of $645,562, an increase of 54.2% over the Q3 2025 figure of $418,553.
• The Company recorded net income of $333,771 in Q3 2026 as compared to net income of $426,171 in Q3 2025.
• The Company had available cash of $1,941,275 as of September 30, 2026, as well as full access to the unutilized revolving credit facility of $1,057,231 (CAD$1,500,000).
• The Company had total principal on demand loans and promissory notes outstanding as of September 30, 2026 of $3,361,493, representing a debt-to-trailing twelve month Adjusted EBITDA ratio of 1.21x.
• As of the current date, the Company has access to up to $3,050,000 in available credit for business acquisitions through its existing credit agreement to support its long-term growth strategy.

President & CEO’s Comments

“The Q3 results provide further evidence that the strategy we have been pursuing is producing results,” said Chris Dobbin, President & CEO. “Nova Leap is scaling and getting stronger in the process. Revenue increased 15.3% year over year, including 8.2% organic revenue growth, while Adjusted EBITDA increased 28.3%. We are generating meaningful organic growth, and earnings are growing faster than revenue. That is the operating leverage we have been working toward, and it is increasingly evident in our financial results.

Trailing twelve-month revenue reached a record $34.9 million and Adjusted EBITDA reached a record $2.79 million. In fact, through the first nine months of 2026, Adjusted EBITDA has already exceeded the full-year 2025 result by 11.3%. We have allocated significant resources investing in our people, our operations and our platform. Those investments are producing results, and we believe there is considerable opportunity ahead of us.

Equally important is our ability to generate cash. We generated approximately $500,000 in free cash flow in each of Q2 and Q3, excluding M&A, and ended Q3 with $1.94 million in cash, relatively modest debt and access to an additional $3.05 million through our acquisition facility. This gives us the financial flexibility to continue investing in our existing operations, pursue acquisitions and be selective about where we deploy capital.

Our capital allocation strategy includes investing in existing operations to support organic growth, opening new locations and pursuing acquisitions at disciplined valuations. Each offers a different path to creating shareholder value. We continue to invest in our established agencies to expand capacity and generate organic growth, as demonstrated by this year’s results. We are also investing in new locations, including Lexington, Kentucky in 2025 and Waltham, Massachusetts this past June. These investments require time and capital before they contribute positively to earnings and cash flow. We believe the potential long-term returns on invested capital from successful new locations can be particularly attractive.

Acquisitions offer a complementary opportunity. They allow us to add established businesses and earnings, expand our market presence and accelerate growth. M&A has been an important part of our history, and we expect it to remain a meaningful component of our capital allocation strategy for years to come. As our existing businesses generate more cash, our capacity to reinvest in organic growth, new locations and acquisitions increases.

Last month, we entered our second decade of operations. The scale we have achieved has also allowed us to broaden our services across the continuum of care through the launch of care management and palliative care, with private nursing planned to follow. These investments expand our ability to serve clients as their care needs evolve while creating additional opportunities for long-term organic growth.

We believe the combination of organic growth, increasing scale, free cash flow and disciplined capital allocation positions Nova Leap to compound shareholder value over many years. Our success will be measured by the value we create for each share. That is the standard we intend to hold ourselves to as capital allocators, and our financial progress gives us increasing confidence in the opportunity ahead.”

This news release should be read in conjunction with the Unaudited Condensed Interim Consolidated Financial Statements for the three and nine months ended September 30, 2026 and 2025 including the notes to the financial statements and Management’s Discussion and Analysis dated November 10, 2026, which have been filed on SEDAR+.

About Nova Leap
Nova Leap is a North American healthcare services company providing home-based and community-based care. Through its network of local agencies, the Company delivers personal care, dementia care, companion services, care management and palliative care, enabling individuals to remain safely and independently in their homes.

Nova Leap operates an integrated platform across the continuum of care, with a focus on scale, operational excellence, and high-quality outcomes for clients and communities.

NON-IFRS AND OTHER MEASURES:

This release contains references to certain measures that do not have a standardized meaning under IFRS Accounting Standards as prescribed by the International Accounting Standards Board (“IASB”) and are therefore unlikely to be comparable to similar measures presented by other companies. Rather, these measures are provided as additional information to complement IFRS Accounting Standards measures by providing a further understanding of operations from management’s perspective. Accordingly, non-IFRS Accounting Standards financial measures should not be considered in isolation or as a substitute for analysis of financial information reported under IFRS Accounting Standards.

The Company presents non-IFRS Accounting Standards financial measures, specifically Adjusted EBITDA (as such term is hereinafter defined), trailing twelve-month Adjusted EBITDA, and the Non-IFRS Accounting Standard ratios debt-to-trailing twelve month Adjusted EBITDA and Adjusted EBITDA margin.

Adjusted Earnings before interest, taxes, amortization and depreciation (“Adjusted EBITDA”) is calculated as income from operating activities plus amortization and depreciation and stock-based compensation expense. The most directly comparable IFRS Accounting Standards measure is income from operating activities.

Trailing twelve-month Adjusted EBITDA represents the aggregate Adjusted EBITDA for the four most recently completed fiscal quarters. The Company believes this measure provides investors with a view of the Company’s operating performance over a continuous twelve-month period and reduces the impact of seasonal fluctuations.

The reconciliation of quarterly and trailing twelve-month Adjusted EBITDA to the income from operating activities is as follows:

	Q3 2026 $	Q3 2025 $	Trailing twelve-month $
Income from operating activities	645,562	418,553	1,953,325
Amortization and depreciation	193,038	233,427	714,579
Stock-based compensation	22,204	18,726	117,544
Adjusted EBITDA	860,804	670,706	2,785,448

The debt-to-trailing twelve-month Adjusted EBITDA ratio is calculated as total principal outstanding on demand loans and promissory notes divided by trailing twelve-month Adjusted EBITDA. The Company believes this ratio provides useful information regarding the Company’s financial leverage and debt capacity. This ratio is presented for information purposes only and should not be considered comparable to leverage ratios calculated by lenders or other issuers.

Adjusted EBITDA margin is calculated by dividing Adjusted EBITDA by revenue for the applicable period. The Company believes Adjusted EBITDA margin provides investors with a useful measure of the Company’s operating profitability and operating leverage by expressing Adjusted EBITDA as a percentage of revenue.

FORWARD LOOKING INFORMATION:

Certain information in this press release may contain forward-looking statements, such as statements regarding future expansions and cost savings and plans regarding future acquisitions and business growth, including anticipated revenue growth, and anticipated consolidated Adjusted EBITDA margins. This information is based on current expectations and assumptions, including assumptions described elsewhere in this release and those concerning general economic and market conditions, availability of working capital necessary for conducting Nova Leap’s operations, availability of desirable acquisition targets and financing to fund such acquisitions, and Nova Leap’s ability to integrate its acquired businesses and maintain previously achieved service hour and revenue levels, that are subject to significant risks and uncertainties that are difficult to predict. Actual results might differ materially from results suggested in any forward-looking statements. All forward-looking statements, including any financial outlook or future-oriented financial information, contained in this press release are made as of the date of this release and included for the purpose of providing information about management’s current expectations and plans relating to the future, and these statements may not be appropriate for other purposes. The Company assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those reflected in the forward-looking statements unless and until required by securities laws applicable to the Company. Additional information identifying risks and uncertainties is contained in the Company’s filings with the Canadian securities regulators, which filings are available at www.sedarplus.com. 

CAUTIONARY STATEMENT:

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Photos accompanying this announcement are available at:

https://www.globenewswire.com/NewsRoom/AttachmentNg/3168fa08-5b49-47f8-8f5e-08a4168d5518

https://www.globenewswire.com/NewsRoom/AttachmentNg/190d5ed8-6c5d-4deb-9d25-65363839852b

CONTACT: For further information:

Chris Dobbin, CPA, ICD.D
Director, President and CEO
T: 902 401 9480
E: cdobbin@novaleaphealth.com